Free Trial

Compare Stocks

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Allarity Therapeutics, Inc. stock logo
ALLR
Allarity Therapeutics
$1.40
-4.1%
$2.80
$1.26
$666.00
$1.98M0.3256,020 shs188,839 shs
Bio-Path Holdings, Inc. stock logo
BPTH
Bio-Path
$0.91
-8.1%
$1.02
$0.85
$13.90
$1.88M0.241.20 million shs140,341 shs
PainReform Ltd. stock logo
PRFX
PainReform
$0.50
-13.8%
$0.60
$0.49
$20.16
$289K0.54166,479 shs137,588 shs
Qualigen Therapeutics, Inc. stock logo
QLGN
Qualigen Therapeutics
$0.10
$0.17
$0.08
$0.80
$1.21M-0.84.67 million shs1.61 million shs
The Best High-Yield Dividend Stocks for 2024 Cover

Looking to generate income with your stock portfolio? Use these ten stocks to generate a safe and reliable source of investment income.

Get This Free Report

Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Allarity Therapeutics, Inc. stock logo
ALLR
Allarity Therapeutics
-5.81%-2.67%-30.81%-72.43%-99.56%
Bio-Path Holdings, Inc. stock logo
BPTH
Bio-Path
-7.48%-8.35%+7.78%-35.48%-92.56%
PainReform Ltd. stock logo
PRFX
PainReform
+3.75%-20.98%-6.05%+46.72%-73.35%
Qualigen Therapeutics, Inc. stock logo
QLGN
Qualigen Therapeutics
-2.00%-40.86%-39.65%-56.23%-86.77%

MarketRank™

CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Allarity Therapeutics, Inc. stock logo
ALLR
Allarity Therapeutics
0.854 of 5 stars
0.04.00.00.02.90.00.6
Bio-Path Holdings, Inc. stock logo
BPTH
Bio-Path
2.1426 of 5 stars
3.52.00.00.03.00.00.6
PainReform Ltd. stock logo
PRFX
PainReform
2.3194 of 5 stars
3.03.00.00.02.41.70.6
Qualigen Therapeutics, Inc. stock logo
QLGN
Qualigen Therapeutics
N/AN/AN/AN/AN/AN/AN/AN/A

Analyst Ratings

CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Allarity Therapeutics, Inc. stock logo
ALLR
Allarity Therapeutics
N/AN/AN/AN/A
Bio-Path Holdings, Inc. stock logo
BPTH
Bio-Path
3.00
Buy$20.002,108.72% Upside
PainReform Ltd. stock logo
PRFX
PainReform
2.00
Hold$2.00300.00% Upside
Qualigen Therapeutics, Inc. stock logo
QLGN
Qualigen Therapeutics
N/AN/AN/AN/A

Current Analyst Ratings

Latest ALLR, QLGN, BPTH, and PRFX Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
10/24/2024
PainReform Ltd. stock logo
PRFX
PainReform
Maxim Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Hold
(Data available from 10/31/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Sales & Book Value

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Allarity Therapeutics, Inc. stock logo
ALLR
Allarity Therapeutics
N/AN/AN/AN/A($559.31) per shareN/A
Bio-Path Holdings, Inc. stock logo
BPTH
Bio-Path
N/AN/AN/AN/A$0.71 per shareN/A
PainReform Ltd. stock logo
PRFX
PainReform
N/AN/AN/AN/A$27.87 per shareN/A
Qualigen Therapeutics, Inc. stock logo
QLGN
Qualigen Therapeutics
$4.98M0.24N/AN/A($0.41) per share-0.24

Profitability & Earnings

CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Allarity Therapeutics, Inc. stock logo
ALLR
Allarity Therapeutics
-$11.90MN/A0.00N/AN/AN/A-2,078.75%-67.89%11/12/2024 (Estimated)
Bio-Path Holdings, Inc. stock logo
BPTH
Bio-Path
-$16.08MN/A0.00N/AN/AN/A-2,842.40%-306.66%11/20/2024 (Estimated)
PainReform Ltd. stock logo
PRFX
PainReform
-$9.34M-$36.83N/AN/AN/A-450.64%-241.33%11/20/2024 (Estimated)
Qualigen Therapeutics, Inc. stock logo
QLGN
Qualigen Therapeutics
-$13.42MN/A0.00N/AN/AN/A-361.85%11/12/2024 (Estimated)

Latest ALLR, QLGN, BPTH, and PRFX Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/15/2024Q2 2024
Bio-Path Holdings, Inc. stock logo
BPTH
Bio-Path
-$1.54-$1.16+$0.38-$1.16N/AN/A    
8/15/2024Q2 2024
PainReform Ltd. stock logo
PRFX
PainReform
N/A-$0.40-$0.40-$0.40N/AN/A
8/14/2024Q2 2024
Qualigen Therapeutics, Inc. stock logo
QLGN
Qualigen Therapeutics
N/A-$0.20-$0.20-$0.19N/AN/A
8/5/2024Q2 2024
Allarity Therapeutics, Inc. stock logo
ALLR
Allarity Therapeutics
N/A-$3.30-$3.30-$0.11N/AN/A

Dividends

CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Allarity Therapeutics, Inc. stock logo
ALLR
Allarity Therapeutics
N/AN/AN/AN/AN/A
Bio-Path Holdings, Inc. stock logo
BPTH
Bio-Path
N/AN/AN/AN/AN/A
PainReform Ltd. stock logo
PRFX
PainReform
N/AN/AN/AN/AN/A
Qualigen Therapeutics, Inc. stock logo
QLGN
Qualigen Therapeutics
N/AN/AN/AN/AN/A

Debt

CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Allarity Therapeutics, Inc. stock logo
ALLR
Allarity Therapeutics
N/A
2.01
2.01
Bio-Path Holdings, Inc. stock logo
BPTH
Bio-Path
N/A
1.67
1.67
PainReform Ltd. stock logo
PRFX
PainReform
N/A
0.61
1.61
Qualigen Therapeutics, Inc. stock logo
QLGN
Qualigen Therapeutics
N/A
0.11
0.11

Ownership

Institutional Ownership

CompanyInstitutional Ownership
Allarity Therapeutics, Inc. stock logo
ALLR
Allarity Therapeutics
11.53%
Bio-Path Holdings, Inc. stock logo
BPTH
Bio-Path
5.74%
PainReform Ltd. stock logo
PRFX
PainReform
37.28%
Qualigen Therapeutics, Inc. stock logo
QLGN
Qualigen Therapeutics
3.18%

Insider Ownership

CompanyInsider Ownership
Allarity Therapeutics, Inc. stock logo
ALLR
Allarity Therapeutics
0.08%
Bio-Path Holdings, Inc. stock logo
BPTH
Bio-Path
3.05%
PainReform Ltd. stock logo
PRFX
PainReform
34.40%
Qualigen Therapeutics, Inc. stock logo
QLGN
Qualigen Therapeutics
1.80%

Miscellaneous

CompanyEmployeesShares OutstandingFree FloatOptionable
Allarity Therapeutics, Inc. stock logo
ALLR
Allarity Therapeutics
51.41 million1.41 millionNot Optionable
Bio-Path Holdings, Inc. stock logo
BPTH
Bio-Path
102.08 million2.47 millionOptionable
PainReform Ltd. stock logo
PRFX
PainReform
4578,000379,000Not Optionable
Qualigen Therapeutics, Inc. stock logo
QLGN
Qualigen Therapeutics
5012.30 million12.08 millionNot Optionable

ALLR, QLGN, BPTH, and PRFX Headlines

Recent News About These Companies

Qualigen Therapeutics, Inc. Announces management changes.
Why Is Qualigen (QLGN) Stock Up 141% Today?

New MarketBeat Followers Over Time

Media Sentiment Over Time

Company Descriptions

Allarity Therapeutics logo

Allarity Therapeutics

NASDAQ:ALLR
Allarity Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing oncology therapeutics using drug-specific companion diagnostics generated by its drug response predictor technology. Its drug candidates include Stenoparib, a poly-ADP-ribose polymerase inhibitor that is in Phase 2 clinical trials for ovarian cancer; Dovitinib, a pan- tyrosine kinase inhibitor for the treatment of renal cell carcinoma; IXEMPRA (ixabepilone), a selective microtubule inhibitor in phase 2 for the treatment of metastatic breast cancer; LiPlaCis, a liposomal formulation of cisplatin, which is in Phase 2 clinical trials for metastatic breast cancer; and 2X-111, a liposomal formulation of doxorubicin that is in Phase 2 clinical trials for metastatic breast cancer and glioblastoma multiforme. Allarity Therapeutics, Inc. has a collaboration with Detsamma Investments Pty. Ltd. to develop Deflexifol for the treatment of solid tumors. The company was incorporated in 2004 and is headquartered in Boston, Massachusetts.
Bio-Path logo

Bio-Path

NASDAQ:BPTH
Bio-Path Holdings, Inc. operates as a clinical and preclinical stage oncology focused RNAi nanoparticle drug development company in the United States. The company develops products based on DNAbilize, a drug delivery and antisense technology platform that uses P-ethoxy, which is a deoxyribonucleic acid (DNA) backbone modification intended to protect the DNA from destruction. Its lead drug candidate is prexigebersen, which is in Phase II clinical trials for the treatment of acute myeloid leukemia (AML) and myelodysplastic syndrome. It is also developing BP1001-A that is in Phase I clinical trial for the treatment of solid tumors; Liposomal Bcl-2 (BP1002), which is in Phase I clinical trial for the treatment of refractory/relapsed lymphoma and chronic lymphocytic leukemia; and Liposomal STAT3 (BP1003) for treating pancreatic cancer, non-small cell lung cancer, and AML. The company was founded in 2007 and is based in Bellaire, Texas.
PainReform logo

PainReform

NASDAQ:PRFX
PainReform Ltd., a clinical stage specialty pharmaceutical company, focuses on the reformulation of established therapeutics and provides an extended period of post-surgical pain relief in Israel. It develops PRF-110, a viscous clear oil-based solution that is instilled directly into the surgical wound to provide localized and extended post-operative analgesia, as well as in Phase 3 clinical trial for pain treatment of patients undergoing bunionectomy and second trial for pain treatment of hernia repair operations. The company was incorporated in 2007 and is based in Tel Aviv, Israel.
Qualigen Therapeutics logo

Qualigen Therapeutics

NASDAQ:QLGN
Qualigen Therapeutics, Inc., a biotechnology company, focuses on the development and commercialization of novel therapeutic products for the treatment of cancer and infectious diseases. It offers FastPack, a patent-protected rapid, onsite immunoassay testing system. The company is developing QN-302 for the treatment of pancreatic ductal adenocarcinoma; QN-247, an oligonucleotide-based drug candidate to treat various nucleolin-expressing cancers, including liquid and solid tumors; QN-165, a drug candidate for the potential broad-spectrum treatment of infectious diseases, such as COVID-19; RAS-F, a small-molecule RAS oncogene protein-protein inhibitor that blocks RAS mutations and inhibits tumor formation; and selective target antigen removal system, a therapeutic device to remove circulating tumor cells, viruses, inflammation factors, and immune checkpoints. Qualigen Therapeutics, Inc. was founded in 1996 and is based in Carlsbad, California.